Global Diabetic Ulcer Treatment Market to Grow at a CAGR of 8.12% During 2021-2026, Driven by the Development of Advanced Technologies

North America is expected to hold a significant share in the overall market growth of diabetic ulcer treatment.  This can be associated with a large percentage of geriatric population, huge investments into research and drug development (R&D) projects, and the growth of the healthcare sector in the region. In addition to this, the sedentary lifestyles and unhealthy eating habits of the people are a leading cause of diabetes in the region, which is growing at an alarming rate, hence necessitating the introduction of an advanced treatment. Apart from this, the launch of highly advanced wound care dressings for the treatment of foot ulcers and the increasing adoption of these treatments by hospitals in the North American region is anticipated to boost the market growth in the region.

RLS Global AB, a significant player in the  global market for diabetic ulcer treatment, recently received regulatory approval for ChloraSolv developed for the treatment of foot ulcers in New Zealand in August 2021. ChloraSolv, known for its unique properties, is expected to deliver positive results with patients suffering from foot ulcers caused by diabetes. With this approval, RLS has established a first market presence in Oceania and is expected to broaden its presence in the market in the coming years. Such developments by market players and the expansion strategies employed by industry players like Medtronic Plc (NYSE: MDT) are leading the growth of the market.

Market Analysis by Treatment Type, Grade, End User, and Region:

• On the basis of treatment type, the market can be broadly divided into wound care dressing, wound care devices, and active therapies. 
• Based on grade, the market can be categorised into grade 1, grade 2, grade 3, grade 4, and grade 5.
• The market, based on end user, can be segmented into hospital inpatient settings, hospital outpatient settings, community health centres, and home health care, among others.
• The major regional markets for the product include North America, Latin America, Europe, the Asia Pacific, and the Middle East and Africa.

Key Findings of the Report:

• The market is primarily being driven by the rise in global diabetes at an alarming rate due to obesity, unhealthy eating habits, and sedentary lifestyles.
• Development of novel techniques to treat mouth ulcers aided by robust pharmaceutical research and development (R&D) is stimulating the growth of the market.
• The robust research programmes aiding in developing advanced wound care products are expected to promote the adoption of advanced treatment options for bettering the healing process of diabetic ulcers, thereby augmenting the growth of the market.
• The market growth is invigorating with the rising awareness about treatment options developed by leading market players and the flourishing healthcare sector.

Key Offerings of the Report:

• The EMR report gives an overview of the global diabetic ulcer treatment industry for the periods (2016-2020) and (2021-2026).
• The report also offers historical (2016-2020) and forecast (2021-2026) markets for treatment types, grades, end users, and major regions of diabetic ulcer treatment.
• The report analyses market dynamics, covering the key demand and price indicators in the market along with an assessment of the SWOT and Porter’s Five Forces Model.

The major players in the global diabetic ulcer treatment market are ConvaTec Group plc, Acelity L.P. Inc., 3M Company, Smith and Nephew Plc., B. Braun Melsungen Ag, Medline Industries, LP, Medtronic Plc, Organogenesis Holdings Inc, Molnlycke Health Care AB, and BSN Medical GMBH, among others. The comprehensive report by EMR looks into the market share, capacity, and latest developments like mergers and acquisitions, plant turnarounds, and capacity expansions of the major players.

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.